Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
Dissolution and liquidation of specified subsidiary デューイ株式会社Disclosing companyADR Biomedical Holdings Inc.
Date of board resolution30 September 2026
Execution Date / Effective DateDissolution resolution date: 30 September 2026; scheduled completion of liquidation: late December 2026 (scheduled)
Target company
Real estate sale and management business
Location Chiyoda-ku, TokyoShare capital ¥10 millionDate of incorporation 14 November 1975
Net Sales¥45 thousand (fiscal year ended March 2026)
Operating profit¥58 thousand (fiscal year ended March 2026)
Net income for the current fiscal year¥1,589 thousand (fiscal year ended March 2026)
Net assets¥75 thousand (fiscal year ended March 2026)
Impact on Business Performance
The impact of this matter on the Company's consolidated results is immaterial, and no revision will be made to the consolidated earnings forecast for the fiscal year ending March 2027.
Procedures and assumptions
Conditions Precedent to ExecutionThe liquidation procedures will be carried out in accordance with applicable laws and regulations.
| Item | Details |
|---|---|
| Transaction name | Dissolution and liquidation of specified subsidiary デューイ株式会社 |
| Name of the Subject Company | デューイ株式会社 |
| Business Description of the Subject Company | Real estate sale and management business |
| Location of the Subject Company | Chiyoda-ku, Tokyo |
| Capital Stock of the Subject Company | ¥10 million |
| Date of Establishment of the Subject Company | 14 November 1975 |
| Net Sales of the Subject Company | ¥45 thousand (fiscal year ended March 2026) |
| Operating Profit of the Subject Company | ¥58 thousand (fiscal year ended March 2026) |
| Net Income of the Subject Company | ¥1,589 thousand (fiscal year ended March 2026) |
| Net Assets of the Subject Company | ¥75 thousand (fiscal year ended March 2026) |
| Voting rights ownership percentage | Before 100％ (after not disclosed) |
| Impact on Business Performance | The impact of this matter on the Company's consolidated results is immaterial, and no revision will be made to the consolidated earnings forecast for the fiscal year ending March 2027. |
| Date of board resolution | 30 September 2026 |
| Execution Date / Effective Date | Dissolution resolution date: 30 September 2026; scheduled completion of liquidation: late December 2026 (scheduled) |
| Conditions Precedent to Execution | The liquidation procedures will be carried out in accordance with applicable laws and regulations. |
Items this document does not state (17)
Counterparty nameAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Contract DateValuation methodologyIndependent valuation institutionSpecial CommitteeManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The decision was made after comprehensively considering the Group's focus of management resources on its medical business, changes in the business environment in recent years, and future profitability.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.